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Glutamate is a major excitatory neurotransmitter that has been 
implicated in memory formation and learning. This acidic amino 
acid also has neurotoxic properties, and in animals produces 
lesions reminiscent of human neurodegenerative diseases. Here 
we present evidence that supports the hypothesis that glutamate 
dysfunction is involved in the pathophysiology of Alzheimer's 
disease and can account for many of the neurochemical and 
behavioral deficits observed in this disease. 
Dementia of the Alzheimer type (DAT) is a 
debilitating neurological disease that affects about 
one in six individuals past the age of sixty ~'2. Its 
etiology is unknown. Patients with DAT suffer severe 
memory loss, personality changes, and symptoms of 
cortical disconnection: apraxias, aphasias and 
agnosias 3-s. The pathological changes in DAT brains 
include the presence of senile plaques, neurofibrillary 
tangles and granulovacuolar degeneration in cere- 
bral cortex, amygdala, olfactory tubercle and 
hippocampus 6-8. Neurochemical studies indicate 
alterations in the cholinergic 9'~°, somatostatiner- 
11 12 13 15 16 17 gic ' , serotonergic - , noradrenergic ' and 
glutamatergic systems ~8-2~. The numerous hypo- 
theses concerning the etiology of this disorder 
include abnormal blood aluminium levels 22'23, viral 
agents 2", lack of trophic factors 25, genetic factors" 
and selective vulnerability of specific neurotrans- 
mitter systems 26-29. 
With respect to selective vulnerability of trans- 
mitter systems, the marked degeneration of 
cholinergic neurons in the basal forebrain has 
received considerable attention 26'28'29. However, 
several features of DAT cannot be explained l:y the 
cholinergic hypothesis. Notably, the regional distri- 
bution of cortical cholinergic innervation from basal 
forebrain does not coincide with the cortical areas 
manifesting the greatest plaque and tangle density 3°. 
Lesions to the cholinergic basal forebrain neurons in 
rats and primates have not been shown to produce 
cortical plaques or tangles. In addition, basal 
forebrain lesions do not produce the somatostatin 31 
and catecholamine 32 deficits seen in DAT. Finally, the 
signs and symptoms of cortical disconnection in DAT 
are difficult to explain solely on the basis of loss of 
cortical cholinergic afferents. Thus, while pathology 
of the ascending cholinergic system is undoubtedly 
present in DAT, it appears that other neurochemical 
systems must be involved in the pathophysiology of 
this disease. 
Recently, the excitatory amino acid neurotrans- 
mitter, glutamate, has been implicated in learning 
and memory 33. A subtype of glutamate receptor, the 
N-methyI-D-aspartate (NMDA) receptor, appears to 
be particularly important in these processes. In 
hippocampus, NMDA-receptor antagonists inhibit 
synaptic transmission in dentate gyrus 3", block the 
development of long-term potentiation (LTP) in vitro 
(a model of memory formation) 3s, and impair spatial 
discrimination learning and LTP in vivo 36. NMDA- 
receptor-mediated excitation has also been observed 
in cerebral cortex 37. The NMDA receptor is coupled 
to a voltage-sensitive cation channel that is gated by 
Mg 2+ (Ref. 38) and blocked by the dissociative 
anaesthetics ketamine and phencyclidine (PCP) 39. 
Both Mg a÷ (Ref. 40) and the dissociative anaesthe- 
tics inhibit the excitatory actions of NMDA 41 and the 
latter block the formation of LTP 42. Furthermore, 
anaesthesia induced with dissociative anaesthetics 
has been reported to produce retrograde and 
anterograde amnesia of events surrounding the 
surgical procedure 43. Thus, impaired glutamate 
receptor function may be associated with learning 
and memory impairments. 
In this regard, glutamate receptors, particularly the 
NMDA subtype, have been shown to be decreased in 
the neocortex of DAT patients compared to age- 
matched controls or Huntington s disease patients :°. 
The largest decreases are seen in the outer cortical 
layers and the CAI and CA2 regions of the 
hippocampus. In the cerebral cortex, total glutamate 
binding is decreased 35-40%, and NMDA receptor 
density is decreased approximately 60%. Decreases 
in quisqualate and NMDA receptor subtypes also are 
observed throughout the CAIICA2 region of the 
hippocampal formation, although changes in NMDA 
receptors are the most prominent, approaching 90% 
loss in stratum pyramidale 44. Muscarinic cholinergic, 
benzodiazepine and high-affinity GABA receptors 
are not significantly changed in these areas ~'45, 
suggesting that the decreased glutamate binding 
does not simply reflect cortical atrophy. Glutamate 
binding is also reduced in the subiculum of DAT 
brains 44. The subiculum is the primary source of 
hippocampal efferent fibers 46 and shows major 
pathology in DAT 8. It is likely that glutamatergic 
neurotransmission in cortex and hippocampal 
formation is severely disrupted. The profound loss of 
glutamate receptors in these regions may provide an 
explanation for the learning and memory deficits that 
are prominent in DAT. 
Symptoms of cortical disconnection are also 
common in DAT. These symptoms might be due to 
the above-mentioned reduction of glutamate 
receptors as well as loss of afferent input. 
Corticocortical association fibers arise from presump- 
tive glutamatergic pyramidal cells 47'48. Their axons 
terminate primarily in superficial and deep layers of 
other cortical regions, largely on spines of the apical 
and basal dendrites of other pyramidal cells 49. In 
DAT, cortical glutamate receptor loss is greatest in 
superficial and deep layers 2°. Senile plaques and 
neurofibrillary tangles are concentrated in zones of 
50 51 association fiber termination ' as well as in layers 
where the cell bodies of these fibers originate 51. 
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Fig. 1. A schematic representation of the course of neuronal degeneration in DA T. Incoming 
glutamate fibers terminate on the spines of apical and basilar dendrites of pyramidal neurons. Early 
in the disease, either due to excess release of  glutamate or abnormal receptor transduction, cellular 
metabolism is altered, spiny processes begin to atrophy and the production of paired helical 
filaments ensues. Later in the disease, neurofibrillary tangles are formed, which further disrupt 
cellular metabolism, and cells begin to die. At the final stages of  DA T, a significant number of large 
pyramidal neurons have died, leaving behind nothing but tangles in place of the missing cells. 
During the course of the disease, the incoming glutamate terminals also degenerate, as their cells of 
origin are also innervated by other glutamate-utilizing neurons. 
Golgi studies of DAT cortex and hippocampus have 
suggested that there is prominent shrinkage of the 
terminal dendrites of pyramidal cells, beginning with 
dendritic spines 52'53. Recent studies from our 
laboratory suggest that glutamate-like immuno- 
reactivity is localized in many pyramidal neurons that 
contain neurofibrillary tangles 54. Thus, cortical 
pathology in DAT seems to include abnormalities in 
the large putative glutamatergic pyramidal neurons, 
their dendritic spines and their glutamatergic 
postsynaptic receptors. 
Whether the alteration in glutamate receptors in 
DAT is simply a reflection of cell loss or is causally 
related to the disease process is an important 
question. Although the reasons for cellular dysfunc- 
tion and death in DAT are unknown, glutamatergic 
dysfunction should be considered as a possible 
etiologic factor. Glutamate and its excitatory analogs 
have well-described neurotoxic ('excitotoxic') prop- 
erties 55. It has been suggested that glutamate 
neurotoxicity is associated with neuronal death in 
, 4 8  5 6 - 5 8  Huntington s disease ' , olivopontocerebellar 
atrophy 59, hypoxia/ischemia 6°,6~, hypoglycemia 62, 
and status epilepticus 6°'63. Some of these neurotoxic 
events may be mediated by the NMDA receptor. 
Antagonists of this receptor inhibit the neuronal 
degeneration associated with insulin-induced hypo- 
glycemia 62, and hypoxia/ischemia 6°. Moreover, 
agonists including NMDA and the endogenous 
tryptophan metabolite quinotinic acid produce axon- 
sparing lesions similar to those produced by other 
glutamate analogues 64. 
Neuronal degeneration approaches 40-80% in 
several regions of the DAT brain 65'66. The neurons 
most frequently lost are the large pyramidal neurons; 
however, the cause of this ceil death is unknown. Cell 
death due to neuronal toxicity could result from 
excessive synthesis or release of glutamate or a 
glutamate-like substance, faulty glutamate re- 
uptake, decreased glutamate degradation, or de- 
creased inhibition of excitatory 
neurons. Any of these aberrant 
processes could, early in the 
disease, increase local levels of 
glutamate and so initiate a slow, 
progressive degeneration and 
eventual death of neurons. Like- 
wise, abnormally enhanced ex- 
citatory postsynaptic mechanisms, 
acting in the presence of normal 
levels of glutamate, could lead to 
cell death. 
Thus, a plausible scenario for 
the sequence of events in DAT can 
be hypothesized (Fig. 1). Early in 
the disease, glutamatergic inputs 
to cortical association and hippo- 
campal pyramidal neurons be- 
come hyperactive (either by 
excessive release, faulty re-uptake 
or altered glutamate receptor 
sensitivity). The excess of excita- 
tion could lead to impaired use of 
the intracellular energy stores and the inability to 
maintain the normal neurofilament structure. As the 
neuron becomes disabled, it would lose the ability to 
maintain its normal level of membrane hyperpolar- 
ization. Voltage-dependent NMDA channels would 
be more easily activated at less negative membrane 
potentials and thus the cell would be even more 
vulnerable to subsequent excitatory input. As part of 
the toxic process, the cell would not be able to 
maintain its extensive axonal and dendritic structure 
and would eventually die. Glutamate receptors 
would be preferentially lost because they are 
concentrated on the spinous processes of distal 
dendrites of pyramidal neurons as opposed to GABA 
and acetylcholine receptors, which are likely to be 
located more proximally. A consequence of this 
hypothesis is that neuronal death would be 
accelerated early in the disease, but as the disease 
progressed cell death would occur more slowly. 
In support of this hypothesis, recent evidence 
suggests that glutamate neurotoxicity can produce 
biochemical changes like those seen in Alzheimer's 
disease. NMDA applied to the cortex produces 
retrograde degeneration of cholinergic neurons in 
the nucleus basalis of rats 67, suggesting that cortical 
glutamatergic neurotoxicity might be responsible for 
the subcortical atrophy previously observed in DAT. 
Excitotoxic applications in the hippocampus have 
produced deficits in local somatostatin levels 31. 
Furthermore, glutamate has been shown to induce 
the formation of structures nearly identical to paired 
helical filaments, the building blocks of neurofibrillary 
tangles, when added to human spinal cord neurons in 
culture 68. Although these studies need to be 
confirmed in cultures of human cortical neurons 
using antibodies against paired helical filaments, they 
lend support to a neurotoxic hypothesis. Finally, in 
post-mortem studies of patients with advanced DAT, 
glutamate concentrations 69 and sodium-dependent 
aspartate binding 7°'71 are decreased compared to 
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age-matched controls, suggesting 
presynaptic glutamatergic dys- 
function. Moreover, in DAT 
patients, cognit ive test scores, 
which progressively decline dur ing 
the course of the disease, correlate 
with the level of glutamate in the 
cerebrospinal f luid 21 reflecting the 
temporal nature of neuronal 
death. 
These data, together with the 
high degree of correspondence 
between the anatomical localiza- 
t ion of plaques and tangles and 
the terminals of proposed gluta- 
mate pathways, support a possible 
connection between glutamate 
and the pathology of DAT. 
A l though the glutamatergic sys- 
tem may be important in the 
clinical manifestations and patho- 
genesis of DAT, this hypothesis 
must be studied in more detail. 
Whatever the cause of DAT, new 
strategies aimed at accurate diag- 
nosis and effective t reatment of 
DAT patients must be explored. 
With the advent of positron 
emission tomography (PET), it is 
now possible to image changes in 
neurotransmitter receptors using 
labelled ligancls 72'73. Glutamate 
receptor ligands have the current 
l imitation that they do not easily 
cross the b lood-bra in barrier. 
However, the dissociative anaes- 
thetics, such as ketamine and 
phencyclidine have ready access 
to the brain and have been found 
to inhibit  the action of N M D A  in a 
non-competi t ive fashion in vitro, 
apparently acting at the associ- 
39 41 ated ion channel ' . We have 
demonstrated a marked concordance in the 
distributions of N M D A  receptors and the sites to 
which the dissociative anaesthetics bind 74 (Fig. 2). 
Since the N M D A  receptor subtype is markedly 
decreased in DAT cortex and hippocampus, labelled 
phencyclidine-l ike drugs or other glutamatergic 
agonists and antagonists may ult imately prove useful 
for the early diagnosis of DAT in vivo using PET 
scanning. 
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W e i z m a n n  Inst i tute, Rehovot ,  76100  Israel, 
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